enGene named Company of the Year by BIOTECanada
in portfolio news
enGene Inc., a biotechnology company focused on the development of a proprietary Gene PillTM platform, has been awarded a prestigious Gold Leaf Award and named Company of the Year by BIOTECanada, Canada’s national biotechnology industry association.
“Everyone at enGene is deeply honored to receive this award from BIOTECanada,” said Dr. Anthony Cheung, President and CEO of enGene. “It recognizes enGene’s significant growth since the start of 2016. Building on our record of partnering success with Johnson & Johnson, we signed a partnership and licensing agreement with Takeda in 2016 to develop several novel therapeutics for gastrointestinal diseases. We also made significant progress developing our innovative oral gene therapy platform, and on boarded a wholly-owned product to our development pipeline that involves targeting PD-L1 expression in the gut for the treatment of acute GvHD and colitis. These achievements would not have been possible without the dedication and outstanding performance of everyone on the enGene team, and the support of our shareholders and board of directors.”